PMID- 16895273
OWN - NLM
STAT- MEDLINE
DCOM- 20071113
LR  - 20181201
IS  - 0027-9684 (Print)
IS  - 0027-9684 (Linking)
VI  - 98
IP  - 7
DP  - 2006 Jul
TI  - Preliminary results of bicalutamide monotherapy on biochemical failure of 
      localized prostate cancer.
PG  - 1058-61
AB  - OBJECTIVES: To prospectively assess the efficacy and tolerability of bicalutamide 
      monotherapy on biochemical failure of localized prostate cancer following total 
      androgen deprivation (TAD) and 3D-conformal radiotherapy (3D-CRT). METHODS: 
      Between January 1998 and January 2002, we prospectively evaluated 20 eligible 
      patients with biochemical failure. All patients were initially treated with 
      neoadjuvant TAD of 12 weeks before 3D-CRT (73.6 Gy at isocenter) and same regimen 
      of TAD after completion of radiotherapy for 24 weeks in high-risk patients. We 
      prescribed 150 mg/day bicalutamide monotherapy for 24 weeks in patients with 
      biochemical failure according to American Society for Therapeutic Radiology and 
      Oncology 1997 consensus definition. Primary end points were biochemical control 
      (BC) and metastasis-free survival (MFS). RESULTS: Median follow-up was 28 months 
      after biochemical failure date. At last visit, the median PSA level of all 
      patients was 2.80 ng/dl while 1.28 ng/dl for nonmetastatic and 30.7 ng/dl for 
      metastatic patients. BC was successfully obtained in five of them with only 
      bicalutamide. Ten patients developed distant metastasis among 15 patients 
      receiving salvage TAD. MFS was 55% at three years for all 20 patients. Temporary 
      gynecomasty was observed in 11 patients as the only serious toxicity. 
      CONCLUSIONS: Bicalutamide monotherapy seems to be a tolerable regimen for 
      patients with biochemical failure following 3D-CRT, and TAD and may be effective 
      in patients with low PSA levels at biochemical failure.
FAU - Akyol, Fadil
AU  - Akyol F
AD  - Departments of Radiation Oncology, Faculty of Medicine, Hacettepe University, 
      Ankara, Turkey.
FAU - Selek, Ugur
AU  - Selek U
FAU - Ozyigit, Gokhan
AU  - Ozyigit G
FAU - Onal, Cem
AU  - Onal C
FAU - Akdogan, Bulent
AU  - Akdogan B
FAU - Karabulut, Erdem
AU  - Karabulut E
FAU - Ozen, Haluk
AU  - Ozen H
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Natl Med Assoc
JT  - Journal of the National Medical Association
JID - 7503090
RN  - 0 (Androgen Antagonists)
RN  - 0 (Anilides)
RN  - 0 (Antineoplastic Agents, Hormonal)
RN  - 0 (Nitriles)
RN  - 0 (Tosyl Compounds)
RN  - 08AN7WA2G0 (Triptorelin Pamoate)
RN  - 0F65R8P09N (Goserelin)
RN  - A0Z3NAU9DP (bicalutamide)
RN  - EC 3.4.21.77 (Prostate-Specific Antigen)
SB  - IM
MH  - Adenocarcinoma/*blood/*radiotherapy
MH  - Aged
MH  - Androgen Antagonists/*therapeutic use
MH  - Anilides/*therapeutic use
MH  - Antineoplastic Agents, Hormonal/*therapeutic use
MH  - Disease Progression
MH  - Follow-Up Studies
MH  - Goserelin/therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoadjuvant Therapy
MH  - Neoplasm Staging
MH  - Nitriles/*therapeutic use
MH  - Prospective Studies
MH  - Prostate-Specific Antigen/*blood
MH  - Prostatic Neoplasms/*blood/*radiotherapy
MH  - Radiotherapy, Adjuvant
MH  - Radiotherapy, Conformal
MH  - Tosyl Compounds/*therapeutic use
MH  - Triptorelin Pamoate/therapeutic use
PMC - PMC2569461
EDAT- 2006/08/10 09:00
MHDA- 2007/11/14 09:00
PMCR- 2006/07/01
CRDT- 2006/08/10 09:00
PHST- 2006/08/10 09:00 [pubmed]
PHST- 2007/11/14 09:00 [medline]
PHST- 2006/08/10 09:00 [entrez]
PHST- 2006/07/01 00:00 [pmc-release]
PST - ppublish
SO  - J Natl Med Assoc. 2006 Jul;98(7):1058-61.